

PUBLIC SUMMARY DOCUMENT

Product: Hollister Moderma Flex Soft Convex High Output

Applicant: Hollister

Date of SPAP Meeting: 20 October 2020

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Hollister, sought listing of the Moderma Flex Soft Convex High Output in subgroup 11(a) of the Stoma Appliance Scheme (SAS) Schedule. The product, including three variants, was proposed for listing at the unit price of \$22.330, with a maximum monthly quantity of 20 units.

2. Comparator

The applicant nominated Coloplast Mio One Piece High Output Soft Convex (SAS Code 80155Q) as the comparator. This product is currently listed in subgroup 11(a) of the SAS Schedule at the unit price of \$22.330 with a maximum monthly quantity of 20 units. The Stoma Product Assessment Panel (SPAP) accepted this product as an appropriate comparator

3. Background

This was the SPAP's first consideration of this product.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a high output pouch.

5. SPAP Comment

Clinical Analysis

The Panel noted that many of the current High Output pouches available on the SAS Schedule connect to a standard collection bag that utilises a 'stepped connector'. The Panel noted that the proposed product has increased the inner diameter of the wide bore tap to 16.5mm and connects to the Hollister High Output Collection Bag, which has a 15mm tube diameter and is available in three sizes.

The Panel agreed the proposed product provides an alternative to what is currently listed in subgroup 11(a) of the SAS Schedule.

Economic Analysis

Not undertaken.

Financial Analysis

The requested price for this product is the same as its accepted comparator. It is therefore, unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product.

6. SPAP Recommendation

The SPAP recommended that the Moderma Flex Soft Convex High Output, including three variants, be listed in subgroup 11(a) of the SAS Schedule at the unit price of \$22.330, with a maximum monthly quantity of 20 units.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Hollister accepts the outcome as noted above by SPAP.